Payment overview · 2025
General Payments
$605.99
41 reported records · 15 companies
Healthcare provider profile · identity verified
David Brian George, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LEBANON, KY · NPI 1376525212
Verified facts
What the public records show
CMS Open Payments records show David Brian George, M.D. received $605.99 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.04 | 33.5% | 18 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $80.09 | 13.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.24 | 8.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.66 | 7.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.00 | 5.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.53 | 4.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.07 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.20 | 3.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.01 | 3.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.12 | 3.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.37 | 3.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.01 | 2.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.64 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.55 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.46 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $605.99 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.40 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.64 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $80.09 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $52.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.66 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.53 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
121 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 732 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 707 | 157 |
| Losartan Potassium | Losartan Potassium | 618 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 449 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 93 |
| Mirtazapine | Mirtazapine | 337 | 66 |
| Lisinopril | Lisinopril | 331 | 77 |
| Eliquis | Apixaban | 289 | 44 |
| Ezetimibe | Ezetimibe | 287 | 71 |
| Furosemide | Furosemide | 284 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 267 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 260 | 57 |
| Omeprazole | Omeprazole | 259 | 56 |
| Spironolactone | Spironolactone | 254 | 58 |
| Carvedilol | Carvedilol | 240 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 60 |
| Sertraline Hcl | Sertraline Hcl | 230 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 204 | 47 |
| Potassium Chloride | Potassium Chloride | 193 | 51 |
| Trazodone Hcl | Trazodone Hcl | 188 | 43 |
| Prednisone | Prednisone | 182 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 62 |
| Gabapentin | Gabapentin | 162 | 41 |
| Valsartan | Valsartan | 160 | 32 |
| Allopurinol | Allopurinol | 155 | 32 |
| Alendronate Sodium | Alendronate Sodium | 149 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 31 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 134 | 134 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 31 |
| Tramadol Hcl | Tramadol Hcl | 127 | 32 |
| Farxiga | Dapagliflozin Propanediol | 126 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 34 |
| Donepezil Hcl | Donepezil Hcl | 121 | 24 |
| Linzess | Linaclotide | 121 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 30 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 116 | 24 |
| Montelukast Sodium | Montelukast Sodium | 109 | 26 |
| Bumetanide | Bumetanide | 108 | 26 |
| Buspirone Hcl | Buspirone Hcl | 108 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 33 |
| Metformin Hcl Er | Metformin Hcl | 103 | 26 |
| Atenolol | Atenolol | 100 | 21 |
| Myrbetriq | Mirabegron | 100 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 94 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 87 | 22 |
| Jardiance | Empagliflozin | 87 | 21 |
| Memantine Hcl | Memantine Hcl | 87 | 18 |
| Lorazepam | Lorazepam | 85 | 26 |
| Simvastatin | Simvastatin | 85 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | suppressed |
| Pregabalin | Pregabalin | 82 | 16 |
| Glipizide Er | Glipizide | 80 | 20 |
| Warfarin Sodium | Warfarin Sodium | 79 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 77 | 20 |
| Alprazolam | Alprazolam | 76 | 12 |
| Metformin Hcl | Metformin Hcl | 72 | 22 |
| Entresto | Sacubitril/Valsartan | 70 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 36 |
| Famotidine | Famotidine | 68 | 19 |
| Irbesartan | Irbesartan | 66 | 14 |
| Ozempic | Semaglutide | 64 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | 15 |
| Digoxin | Digoxin | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 59 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 27 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 29 |
| Finasteride | Finasteride | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 30 |
| Nitroglycerin | Nitroglycerin | 44 | 29 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Lactulose | Lactulose | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 38 | 13 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Clotrimazole | Clotrimazole | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 24 |
| Trulicity | Dulaglutide | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 25 |
| Cephalexin | Cephalexin | 31 | 18 |
| Nystatin | Nystatin | 31 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 23 |
| Topiramate | Topiramate | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 22 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 26 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Eplerenone | Eplerenone | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Prolia | Denosumab | 22 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 13 |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Constulose | Lactulose | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Testosterone | Testosterone | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 12 |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Felodipine Er | Felodipine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $605.99 · 41 records | Novo Nordisk Inc | ACCRUFER, APTIMA, DAYBUE, EVENITY, FARXIGA, JARDIANCE, Korlym, LEQVIO, Ohtuvayre, Ozempic, Rybelsus, SKYCLARYS, VENASEAL, VRAYLAR, Wegovy, XIFAXAN, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error